Maria Vogiatzi, MD, Division of Endocrinology at the Children’s Hospital of Philadelphia, discusses the effect of Crenessity (crinecerfont) on bone age advancement in patients with congenital adrenal hyperplasia (CAH).
CAH refers to a group of genetic conditions that affect the adrenal gland production of hormones, particularly, the production of cortisol and androgen hormones. Persons with severe forms of the condition can be dramatically impacted. For example, females with a severe form of the condition may have ambiguous genitalia at birth and if not properly diagnosed, develop dehydration, poor feeding, diarrhea, vomiting and other health problems soon after. People with milder forms may not be diagnosed with the condition until adolescence or adulthood when they experience early signs of puberty or fertility problems. Excess androgens can also cause accelerated bone age maturation, leading to reduced adult height.
An abstract presented at ENDO 2026 aimed to describe changes in bone age advancement and predicted adult height in a subset of phase 3 CAHtalyst Pediatric (NCT04806451) participants. Crinecerfont is a first-in-class corticotropin-releasing factor type 1 receptor (CRF1) antagonist that is approved by the US Food and Drug Administration (FDA) as an adjunct to glucocorticoid replacement in patients 4 years of age and older with classic CAH.
A total of 103 participants were randomized and 41 had available assessments at baseline and month 24 of the study. Of these 41 participants, 63% had an advanced bone age at baseline. At month 24, 15% of these patients showed worsening bone age advancement, 31% showed no change, and 27% had improvements in bone age minus chronological age from 6 months up to 1 year. Additionally, 27% of participants had improvements in bone age minus chronological age of 1 year or more.
For more information, click here.
To learn more about CAH and other rare endocrine disorders, visit https://checkrare.com/diseases/endocrine-disorders/